Rosiglitazone-induced granulomatous hepatitis.
Granulomatous hepatitis has many causes. Drugs are an important etiologic factor. Several oral hypoglycemic agents are available for treatment of type II diabetes. Rosiglitazone, a thiazolidinedione, is a newer agent in this class. It has not been shown to be hepatotoxic in the premarketing trials. However, a few case reports have implicated it as a cause of acute hepatocellular injury. The authors report a case of granulomatous hepatitis associated with use of rosiglitazone. Liver function tests should be done regularly to monitor patients on this medication.
Dhawan
Manish
M
Department of Gastroenterology, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212, U.S.A.
Agrawal
Radheshyam
R
Ravi
Jan
J
Gulati
Sangeeta
S
Silverman
Jan
J
Nathan
Girija
G
Raab
Stephen
S
Brodmerkel
George
G
D000328:Adult; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D006099:Granuloma / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008297:Male; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D045162:Thiazolidinediones; D013997:Time Factors
D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone